Telix Pharmaceuticals entered into an agreement to acquire Dedicaid GmbH

Telix Pharmaceuticals Limited (ASX: TLX) has signed an agreement to acquire Dedicaid GmbH (Dedicaid), located in Vienna, a spin-off of the Medical University Vienna, for the expansion of its artificial intelligence (AI) capability. To use with other imaging modalities and positron emission tomography (PET), Dedicaid’s AI platform can rapidly generate indication-specific clinical decision support (CDSS) applications from available datasets. It can predict risk to the patient and the severity of the disease and inform treatment decisions.

This acquisition will give Telix the ability to rapidly generate CDSS applications that are highly complementary to its radiopharmaceutical pipeline. Following completion of the transaction, the company aims to finalise validation activities and regulatory submissions for the AI platform as a ‘software as a medical device’ during 2023.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com